Short answer
MERIT MEDICAL SYSTEMS INC (MMSI) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3), Item 7.01 (Regulation FD Disclosure). Q3 2026 earnings release for quarter ended September 30, 2026.
MERIT MEDICAL SYSTEMS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 earnings release for quarter ended September 30, 2026
- Results and management commentary available in Exhibit 99.1, relevant for updating revenue, profitability and outlook expectations
Item 7.01 · Regulation FD Disclosure
- Q3 2026 results covered quarter ended September 30, 2026, with conference call and presentation on October 29, 2026
- Solo Pace acquisition closed October 13, 2026 for approximately $45 million cash
- Transaction expands Merit’s portfolio, with acquisition-related costs potentially affecting GAAP results
- Management presented non-GAAP results, but excludes certain acquisition, amortization, litigation and compensation impacts from forward-looking GAAP guidance
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $416.2M, up 8.4%, with 9% organic constant-currency growth, signaling broad underlying demand strength
- GAAP operating margin 14.1% vs 11.1%, while non-GAAP margin reached 21.3% vs 19.7%, indicating improved operating leverage
- GAAP EPS $0.70, up 51%, and non-GAAP EPS $1.12, up 22%, materially ahead of revenue growth
- Therapeutic revenue rose 14%, led by Endoscopy up 33% and Therapeutic OEM up 32%; Foundational growth was 6%
- 2026 guidance raised: revenue $1.635-$1.642B and non-GAAP EPS $4.33-$4.37, with cash $503.6M and debt $747.5M at September 30
Item EX-99.2 · Exhibit EX-99.2
- Q3 revenue $416.2M, up 8.4% year over year, with domestic growth of 11.0% outpacing international growth of 4.4%
- GAAP operating margin 14.1% versus 11.1%, while net income rose 52.4% to $42.3M and EPS increased 51.3% to $0.70
- Non-GAAP EPS $1.12, up 21.7%, indicating stronger underlying earnings despite acquisition, amortization, and debt-related adjustments
- Operating cash flow fell to $65.3M from $75.0M, a key counterpoint to the earnings improvement
- 2026 guidance raised: revenue $1.635B-$1.642B and non-GAAP EPS $4.33-$4.37, with constant-currency growth of 7.0%-7.5%
Item EX-99.3 · Exhibit EX-99.3
- Merit acquired Solo Pace’s remaining equity on October 13, 2026 for approximately $45 million, following its prior 18% ownership
- Adds proprietary temporary pacing systems for TAVR and other transcatheter heart-valve procedures to Merit’s Cardiac Therapies platform
- 2026 financial impact immaterial, limiting near-term earnings significance despite strategic portfolio expansion
- 2027 non-GAAP earnings slightly accretive, including approximately $1.5 million lower interest income and excluding $3.2 million transaction expenses
- 2027 GAAP earnings slightly dilutive, with accretion expected thereafter contingent on commercialization and integration execution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MERIT MEDICAL SYSTEMS INC 8-K filings
Get the next MMSI 8-K as it lands
Follow MMSI for push alerts, or ask the research agent what this filing means.